Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) Short Interest Update

Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) was the target of a significant increase in short interest in September. As of September 30th, there was short interest totalling 122,300 shares, an increase of 86.7% from the September 15th total of 65,500 shares. Approximately 0.7% of the company’s shares are short sold. Based on an average trading volume of 115,500 shares, the short-interest ratio is presently 1.1 days.

Inspira Technologies Oxy B.H.N. Stock Performance

IINN stock opened at $1.39 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.13 and a current ratio of 2.23. Inspira Technologies Oxy B.H.N. has a 52-week low of $0.76 and a 52-week high of $2.49. The company’s 50 day simple moving average is $1.17 and its 200-day simple moving average is $1.55.

Institutional Trading of Inspira Technologies Oxy B.H.N.

An institutional investor recently bought a new position in Inspira Technologies Oxy B.H.N. stock. Renaissance Technologies LLC bought a new stake in Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 24,497 shares of the company’s stock, valued at approximately $34,000. Renaissance Technologies LLC owned 0.19% of Inspira Technologies Oxy B.H.N. at the end of the most recent reporting period. Institutional investors own 12.72% of the company’s stock.

About Inspira Technologies Oxy B.H.N.

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels.